LifeSignals Receives US FDA Clearance To Market ECG Remote Monitoring Platform

LifeSignals received 510(k) clearance for its Wireless Medical Biosensor LP1250, which can be integrated into third-party devices to remotely monitor patients for common cardiac arrythmias.

Heart beat icon

Fremont, CA-based LifeSignals, Inc. announced on 21 July it received 510(k) clearance from the US Food and Drug Administration to market its electrocardiogram (ECG) remote monitoring patch platform LP1250 for patients in ambulatory, hospital, home and health care settings.

This comes just two months after the patch earned a CE mark for monitoring patients in the same health care...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Approvals

More from Policy & Regulation